Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (NCT07361484) titled 'Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)' on Jan. 19.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: BeyondSpring Pharmaceuticals Inc.
Condition:
Non-Small Cell Lung Cancer
Non-squamous Non-Small Cell Lung Cance
Intervention:
Drug: Plinabulin
Drug: Docetaxel
Recruitment Status: Not recruiting
Phase: Phase 3
Date...